DIPHERELINE® (triptorelin embonate) 22.5mg Paediatric Product Familiarisation Program (PFP)

DIPHERELINE® (triptorelin embonate) 22.5mg Paediatric Product Familiarisation Program (PFP)

Diphereline® (triptorelin embonate) 22.5mg is now approved as a treatment for children with Central Precocious Puberty (CPP). It is the first and only six-month formulation that is TGA-approved for children with CPP in Australia. Diphereline® is a Gonadotrophin Releasing Hormone agonists (GnRHa) and is administered as an intramuscular injection.1

Please carefully read the Detailed Info tab.

Terms & Conditions

  • I am a pediatric-endocrinologist*
  • I have read the Diphereline® Product Information*
  • I will enrol eligible patients to the Diphereline 22.5mg PFP and confirm that the patient/carer understands the program and consents to the terms of the PFP*
  • I will order and use Diphereline® 22.5mg 6-month as per TGA-approval and eligibility criteria listed above*
  • I will provide the Consumer Medicines Information to my eligible patient(s)/carer(s); and I will only commence treatment with Diphereline® 22.5mg after consultation with my eligible patient(s)/carer(s)*
  • I will report any adverse events that occur in my patients during the use of Diphereline® 22.5mg to Ipsen (pharmacovigilance.australia@ipsen.com) or directly to the TGA (aems.tga.gov.au)*

Communications from Ipsen

  • Ipsen may communicate with me via email, print and/or SMS about Ipsen’s products in the following areas: Medical and Scientific Updates, Event Notifications, Corporate Information and Branded Product Information. If I no longer wish to receive communications from Ipsen, I can manage my preferences and unsubscribe using the link at the bottom of Ipsen’s emails and SMS’s. Alternatively, I can contact the privacy officer at privacyofficer.au@ipsen.com.


I agree to receive communications from Ipsen (optional)
I have read and agree to the T&C above (*mandatory)Clear
Sorry, but you do not have permission to view this content.